Novel hypoxia–immune biomarkers predict response to neoadjuvant chemotherapy in patients with laryngo-hypopharyngeal cancer
Lingwa Wang, Haiyang Li, Ling Feng, Jugao Fang, Ru Wang · 2025
Read Novel hypoxia–immune biomarkers predict response to neoadjuvant chemotherapy in patients with laryngo-hypopharyngeal cancer by Lingwa Wang, Haiyang Li, Ling Feng, Jugao Fang, Ru Wang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12751945.txt.
Description
Lingwa Wang and co-authors build, in a 2025 study, a five-gene test that forecasts how throat and voice-box cancers will respond to chemotherapy given before surgery. The tumor's low-oxygen, immune-linked setting shapes that response. Gene sequencing found forty genes that differed between groups and tied to both oxygen lack and immunity.
The five-gene model scored well at telling responders from non-responders. Patients in the high-risk group lived shorter lives, both in the team's data and in a public cancer data set. Immune cell patterns, above all natural killer cells, helped explain drug response. One gene also flagged sensitivity to two targeted drugs, which may guide backup plans when chemotherapy fails.
Catalog record
| CREATOR | Lingwa Wang, Haiyang Li, Ling Feng, Jugao Fang, Ru Wang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |